Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 7;7(9):1174-80.
doi: 10.7150/jca.15243. eCollection 2016.

Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience

Yoon Jung Oh  1 , Seong Yoon Yi  2 , Ki Hyang Kim  3 , Yong Jin Cho  4 , Seung Hoon Beum  5 , Young Han Lee  6 , Jin-Suck Suh  6 , Hyuk Hur  7 , Kyung Sik Kim  7 , Sung Hoon Kim  8 , Young Deuk Choi  9 , Kyoo-Ho Shin  4 , Hyun Jung Jun  10 , Sung Joo Kim  11 , Jeeyun Lee  12 , Se Hoon Park  12 , Sung Hoon Noh  7 , Sun Young Rha  5 , Hyo Song Kim  5
Affiliations

Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience

Yoon Jung Oh et al. J Cancer. .

Abstract

Purpose: We performed this study to analyze the clinical features and prognosis of Korean patients with liposarcoma.

Patients & methods: Between October 1986 and April 2013, 231 patients who were diagnosed with liposarcoma by histologic examination were enrolled in this study.

Results: The distribution of histologic subtypes was well-differentiated (n = 97, 42%), myxoid (n = 74, 32%), dedifferentiated (n = 32, 13.9%), pleomorphic (n = 15, 6.5%), and round-cell liposarcoma (n = 13, 5.6%). The majority of liposarcomas were located in the lower extremities (35.5%) and retroperitoneum (34.2%). Prognosis was worse for the trunk group compared with the extremity group (median disease-free survival [DFS] 3.3 vs. 9.9 years, respectively, P <0.001). Median DFS was significantly worse in patients with high grade histology compared to those with low grade histology (16.9% vs. 65.7%, P <0.001). The independent prognostic factors associated with survival were histology (hazard ratio [HR] 3.01; 95% confidence interval [CI], 1.82-4.97; P <0.001) and primary site (HR 1.80; 95% CI, 1.12-2.89; P = 0.015). Three risk groups with different survival outcomes were identified: group 1 (n = 98), no risk factors; group 2 (n = 92), one risk factor; and group 3 (n = 41), two risk factors.

Conclusions: Histologic subtype and primary site were independent prognostic factors for curatively resected liposarcoma. A prognostic model for patients with liposarcoma clarified distinct groups of patients with good prognostic discrimination.

Keywords: Asian; Liposarcoma; Prognostic model; Survival..

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Survival outcome according to histologic subtypes. (A) DFS and (B) OS.
Figure 2
Figure 2
Survival outcome according to primary site. DFS (A) and OS (B) for each primary site. DFS (C) and OS (D) for the trunk and extremity sites.
Figure 3
Figure 3
DFS (A) and OS (B) by prognostic model. Group 1, no risk factor; group 2, one risk factor, group 3, two risk factors.
See this image and copyright information in PMC

References

    1. Dodd LG. Update on liposarcoma: a review for cytopathologists. Diagnostic cytopathology. 2012;40:1122–31. - PubMed
    1. Lemeur M, Mattei JC, Souteyrand P, Chagnaud C, Curvale G, Rochwerger A. Prognostic factors for the recurrence of myxoid liposarcoma: 20 cases with up to 8 years follow-up. Orthopaedics & traumatology, surgery & research: OTSR. 2015;101:103–7. - PubMed
    1. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer. 2006;119:2922–30. - PubMed
    1. Matthyssens LE, Creytens D, Ceelen WP. Retroperitoneal liposarcoma: current insights in diagnosis and treatment. Frontiers in surgery. 2015;2:4. - PMC - PubMed
    1. Gemici K, Buldu I, Acar T, Alptekin H, Kaynar M, Tekinarslan E. et al. Management of patients with retroperitoneal tumors and a review of the literature. World journal of surgical oncology. 2015;13:143. - PMC - PubMed